封面
市場調查報告書
商品編碼
1362931

黑色素瘤治療藥物市場規模、佔有率和趨勢分析報告:按產品、藥物類型、地區和細分市場預測,2023-2030年

Melanoma Therapeutics Market Size, Share & Trends Analysis Report By Product (Chemotherapy, Immunotherapy), By Drug Type (Branded Drugs, Generic Drugs), By Region, And Segment Forecasts, 2023 - 2030

出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

黑色素瘤治療藥物市場成長與趨勢:

Grand View Research, Inc.最新報告顯示,預計到2030年,全球黑色素瘤治療藥物市場規模將達到109.8億美元,2023年至2030年年複合成長率為10.3%。

黑色素瘤、皮膚癌和皮膚過敏等慢性疾病發生率的增加是市場的關鍵促進因素。

據 CDC 指出,2013年有超過 71,943 人罹患黑色素瘤。美國癌症協會預測,2017年這一數字將增至 87,100 例,凸顯了預測期內對黑色素瘤治療藥物的需求。

FDA核准的增加以及療效增強的新療法的推出預計也將提供成長機會。從2011年到2016年的六年年度裡,八種生物製藥核准用於治療黑色素瘤:Opdivo、Yervoy、Kotelic、Zerbolav、Keytruda、Mekinist、Tafinlar 和 Imridic。

本公司進行各種研發活動,以發現現有產品的新適應症並開發創新分子。例如,2014年9月,美國FDA核准專利藥物Keytruda(Merck & Co., Inc.)用於治療轉移性黑色素瘤,擴大了該產品的治療適應症。該藥物最初核准用於治療非小細胞肺癌。

此外,美國的許多製藥公司致力於開發新的生物製藥。例如,2017年3月,第一三共株式會社宣布了一項聯合藥物研發計畫-接受藥物發現新挑戰(TaNeDS)-透過聯合研究促進開發新藥。也與AgonOX, Inc.建立了策略研究聯盟,致力於開發免疫學和癌症領域的新型免疫療法藥物。預測期內新產品的核准預計將推動市場成長。

黑色素瘤治療藥物市場報告亮點

  • 由於副作用較少、效率較高等優勢,預計標靶治療領域在預測期內將出現 11.9%的良好成長。
  • 由於專利的排他性,品牌藥在2022年佔據產業91.33%的壓倒性市場。
  • 由於採用率增加和治療效果提高等優勢,Opdivo 和 Kotelic 等生物製藥預計將在預測期內顯示出良好的成長。
  • Yervoy 的專利在美國和歐洲分別於2022年和2020年到期。預計這將為新參與企業提供成長機會。
  • 預計亞太地區在預測期內將呈現 11.6%的年複合成長率。
  • 主要市場參與企業加強研發力度,以發現和開發黑色素瘤治療的新藥。

目錄

第1章 調查方法和範圍

第2章 執行摘要

第3章 黑色素瘤治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 黑色素瘤治療藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 黑色素瘤治療藥物:產品估算與趨勢分析

  • 黑色素瘤藥物市場:重點
  • 黑色素瘤治療藥物市場:2022年和2030年趨勢和市場佔有率分析
  • 化療
  • 免疫療法
  • 標靶治療
  • 放射治療

第5章 治療藥物:藥物種類估算及趨勢分析

  • 黑色素瘤藥物市場:重點
  • 黑色素瘤治療藥物市場:2022年和2030年趨勢和市場佔有率分析
  • 品牌藥品
  • 學名藥

第6章 黑色素瘤治療藥物市場:區域估計與趨勢分析

  • 區域展望
  • 依地區分類的黑色素瘤藥物市場:要點
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東、非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭分類
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Novartis AG
    • Merck & Co, Inc.
    • Amgen Inc.
    • F. Hoffman-La Roche Ltd.
    • Abbott Laboratories
Product Code: GVR-1-68038-535-9

Melanoma Therapeutics Market Growth & Trends:

The global melanoma therapeutics market size is expected to reach USD 10.98 billion by 2030, registering a CAGR of 10.3% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing incidence of chronic diseases such as melanoma, skin cancer, and skin allergies is an important driver of the market.

According to the CDC, over 71,943 people were affected by melanoma in 2013. The American Cancer Society estimates that this number will go up to 87,100 in 2017, thus highlighting the need for melanoma drugs over the forecast period.

Increasing number of FDA approvals and the introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which includes Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.

Companies are undertaking various R&D activities to find new indications for existing products and the development of innovative molecules. For instance, in September 2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the therapeutic application of its product. This drug was initially approved for the treatment of non-small cell lung cancer.

Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia Pacific are focusing on the development of new biologics. For instance, in March 2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery project-Take a New Challenge for Drug discovery (TaNeDS)-to facilitate new drug development through collaborations. Moreover, it entered into a strategic research collaboration with AgonOX, Inc. to develop new immunotherapy drugs for the immuno-oncology segment. The approval of novel products over the forecast period is anticipated to boost the market growth.

Melanoma Therapeutics Market Report Highlights:

  • Targeted therapy segment is expected to show lucrative growth of 11.9% over the forecast periodowing to benefits such as low adverse effects and higher efficiency
  • Branded drugs held a dominant share of 91.33% in 2022 of the industry because of patent exclusivity
  • Biologics, such as Opdivo and Cotellic, are expected to exhibit lucrative growth over the forecast period owing to increase adoption and advantages such as improved therapeutic effects
  • The patent for Yervoy will expire in 2022 in the U.S. and in 2020 in Europe. This is expected to provide growth opportunities for new market entrants
  • Asia Pacific is expected to exhibit lucrative CAGR of 11.6% over the forecast period
  • Key market players are increasing R&D efforts for the discovery and development of novel drugs for the treatment of melanoma

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Drug type
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Drug type outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market drivers analysis
    • 3.3.2. Market restraints analysis
  • 3.4. Melanoma Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis

  • 4.1. Melanoma Therapeutics Market: Key Takeaways
  • 4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Radiation Therapy
    • 4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis

  • 5.1. Melanoma Therapeutics Market: Key Takeaways
  • 5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Branded Drugs
    • 5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Generic Drugs
    • 5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Melanoma Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Bristol-Myers Squibb Company
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. AstraZeneca
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Novartis AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Merck & Co, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Amgen Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. F. Hoffman-La Roche Ltd.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Abbott Laboratories.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives=

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 60 Kuwait melanoma therapeutics market, by drug type, (USD Million) 2018 - 2030Report SummaryTable of ContentsSegmentationMethodologyRequest a FREE Sample Copy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Drug type
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Drug type outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Melanoma Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market drivers analysis
    • 3.3.2. Market restraints analysis
  • 3.4. Melanoma Therapeutics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Melanoma Therapeutics: Product Estimates & Trend Analysis

  • 4.1. Melanoma Therapeutics Market: Key Takeaways
  • 4.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Chemotherapy
    • 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted therapy estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Radiation Therapy
    • 4.6.1. Radiation therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Melanoma Therapeutics: Drug Type Estimates & Trend Analysis

  • 5.1. Melanoma Therapeutics Market: Key Takeaways
  • 5.2. Melanoma Therapeutics Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Branded Drugs
    • 5.3.1. Branded drugs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Generic Drugs
    • 5.4.1. Generic drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Melanoma Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Melanoma Therapeutics Market by Region: Key Takeaways
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
    • 7.2.1. Bristol-Myers Squibb Company
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. AstraZeneca
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Novartis AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Merck & Co, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Amgen Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. F. Hoffman-La Roche Ltd.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Abbott Laboratories.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 4 North America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 Canada melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 9 Europe melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 10 Europe melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 11 Europe melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 13 Germany melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 14 UK melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 15 UK melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 16 France melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 17 France melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 18 Italy melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 19 Italy melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 Spain melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 21 Spain melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 22 Sweden melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 23 Sweden melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 24 Norway melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 25 Norway melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 Denmark melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 27 Denmark melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 31 China melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 32 China melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 33 Japan melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 34 Japan melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 India melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 36 India melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 37 Thailand melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 38 Thailand melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 39 South Korea melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 40 South Korea melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 41 Latin America melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 42 Latin America melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 43 Latin America melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 44 Brazil melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 45 Brazil melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 46 Mexico melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 47 Mexico melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 48 Argentina melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 49 Argentina melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa melanoma therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 53 South Africa melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 54 South Africa melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 57 UAE melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 58 UAE melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)
  • Table 59 Kuwait melanoma therapeutics market, by product, 2018 - 2030 (USD Million)
  • Table 60 Kuwait melanoma therapeutics market, by drug type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Melanoma therapeutics: market outlook
  • Fig. 9 Melanoma therapeutics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Melanoma therapeutics market driver impact
  • Fig. 15 Melanoma therapeutics market strategic initiatives analysis
  • Fig. 16 Melanoma therapeutics market: Product movement analysis
  • Fig. 17 Melanoma therapeutics market: Product outlook and key takeaways
  • Fig. 18 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Radiation therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Melanoma therapeutics market: Drug type movement analysis
  • Fig. 23 Melanoma therapeutics market: Drug type and key takeaways
  • Fig. 24 Branded drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Generic drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Global melanoma therapeutics market: Regional movement analysis
  • Fig. 27 Global melanoma therapeutics market: Regional outlook and key takeaways
  • Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)